Maintaining hormone levels after menopause may reduce the risk of Alzheimer’s, new research finds.

Clinical Trials Arena speaks with Pentara's Sam Dickson about the dos and don'ts for Alzheimer's study design with diversity in mind.

A researcher told Newsweek the findings could help doctors match more patients to treatment and trials.

GLP-1 receptors are present in key brain regions involved in memory and cognition, thus linking their activation to cell survival, metabolism, and synaptic function. Preclinical data suggest that ...

FDA clears PhenoNet Inc. to advance PHENOGENE-1A into Phase 3 trials for early Alzheimer’s disease, including APOE4 and non-APOE4 patients.

The tests aren’t a guarantee that someone will develop dementia, but that hasn’t stopped people from getting them.

(Yana Iskayeva/Moment/Getty Images) Alzheimer's disease is an incredibly challenging condition to study, because of both its ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A blood-thinning medication already taken by millions of people for an ...

COVID-19 may increase the risk of Alzheimer’s disease, especially for those who experience a severe infection. COVID-19 causes inflammation and other physiological changes in the brain that are ...

Bill Ritter is opening up about how his life has changed since an early-stage Alzheimer’s diagnosis ended his long run at the WABC anchor desk. ... Read More ...